Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Jefferies Financial Group Inc. bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 187,897 shares of the biopharmaceutical company's stock, valued at approximately $1,533,000. Jefferies Financial Group Inc. owned approximately 0.06% of Amicus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics in the 4th quarter valued at $29,000. Covestor Ltd lifted its stake in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at $59,000. GAMMA Investing LLC boosted its holdings in Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth $104,000.

Amicus Therapeutics Stock Down 2.5%

Shares of FOLD stock traded down $0.18 during mid-day trading on Thursday, reaching $6.76. 2,278,475 shares of the company's stock traded hands, compared to its average volume of 3,865,655. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The company's 50-day moving average price is $6.10 and its 200-day moving average price is $7.40. The company has a market cap of $2.08 billion, a P/E ratio of -56.37 and a beta of 0.53.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on FOLD shares. The Goldman Sachs Group dropped their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Wall Street Zen raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.